Medtronic (MDT) Expected to Release Earnings on Tuesday

Key Points

• Medtronic is expected to report Q1 fiscal 2027 results before the market opens Tuesday, September 1. Analysts forecast earnings of $1.39 per share on $9.55 billion in revenue, compared with the company’s full-year EPS guidance of $5.90–$6.00.
• The company’s latest quarter exceeded expectations, with EPS of $1.55 versus the $1.54 consensus and revenue of $9.81 billion, up 9.9% year over year.
• Medtronic recently declared a quarterly dividend of $0.72 per share, implying a 3.1% yield, while analysts maintain a “Moderate Buy” consensus and an average price target of $98.83.

Medtronic (NYSE:MDT - Get Free Report) is expected to release its Q1 2027 results before the market opens on Tuesday, September 1st. Analysts expect the company to post earnings of $1.39 per share and revenue of $9.5458 billion for the quarter. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Parties may review the information on the company's upcoming Q1 2027 earning report page for the latest details on the call scheduled for Tuesday, September 1, 2026 at 7:45 AM ET.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. On average, analysts expect Medtronic to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Price Performance

Shares of MDT opened at $92.92 on Tuesday. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The business's 50 day moving average price is $84.64 and its two-hundred day moving average price is $85.87. The firm has a market cap of $118.94 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 2.50 and a beta of 0.55.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio is currently 77.21%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm's stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company's stock.

Hedge Funds Weigh In On Medtronic

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Medtronic by 1.0% during the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock worth $5,800,550,000 after acquiring an additional 625,992 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Medtronic by 0.4% in the fourth quarter. Raymond James Financial Inc. now owns 11,253,611 shares of the medical technology company's stock valued at $1,081,940,000 after purchasing an additional 49,746 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Medtronic by 35.3% during the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock valued at $970,456,000 after purchasing an additional 2,658,981 shares during the period. Schroder Investment Management Group lifted its holdings in Medtronic by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 8,468,982 shares of the medical technology company's stock worth $813,530,000 after purchasing an additional 939,133 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Medtronic by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,310,995 shares of the medical technology company's stock worth $798,354,000 after purchasing an additional 135,204 shares in the last quarter. Institutional investors own 82.06% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Leerink Partners decreased their price target on shares of Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a research note on Thursday, June 4th. Wall Street Zen raised shares of Medtronic from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Royal Bank Of Canada restated an "outperform" rating and issued a $118.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Stifel Nicolaus set a $80.00 target price on Medtronic in a research report on Wednesday, June 3rd. Finally, The Goldman Sachs Group dropped their price target on Medtronic from $84.00 to $83.00 and set a "neutral" rating on the stock in a research note on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.83.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source